Sarepta Therapeutics Inc (1SRPT)

Currency in EUR
10.19
+0.05(+0.49%)
Closed·
1SRPT Scorecard
Full Analysis
RSI suggests the stock is in oversold territory
Trading near 52-week Low
Fair Value
Day's Range
9.3310.40
52 wk Range
9.3337.16
Key Statistics
Prev. Close
10.19
Open
10.38
Day's Range
9.33-10.4
52 wk Range
9.33-37.16
Volume
5.39K
Average Volume (3m)
4.4K
1-Year Change
-
Book Value / Share
10.89
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
1SRPT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Sarepta Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Sarepta Therapeutics Inc Company Profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children’s Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Industry
-
Sector
-
Employees
1372
Market
Italy

Compare 1SRPT to Peers and Sector

Metrics to compare
1SRPT
Peers
Sector
Relationship
P/E Ratio
−4.7x−3.9x−0.5x
PEG Ratio
0.00−0.090.00
Price/Book
1.0x1.8x2.6x
Price / LTM Sales
0.5x4.0x3.2x
Upside (Analyst Target)
-83.4%41.6%
Fair Value Upside
Unlock5.3%6.0%Unlock

Earnings

Latest Release
May 06, 2025
EPS / Forecast
-4.60 / --
Revenue / Forecast
744.86M / --
EPS Revisions
Last 90 days

1SRPT Income Statement

People Also Watch

28.39
CNC
+6.09%
39.80
BMNR
-4.67%
115.62
CRWV
-3.65%
62.08
MP
+0.84%
54.335
ASTS
-9.53%

FAQ

What Stock Exchange Does Sarepta Therapeutics Inc Trade On?

Sarepta Therapeutics Inc is listed and trades on the Milan Stock Exchange stock exchange.

What Is the Stock Symbol for Sarepta Therapeutics Inc?

The stock symbol for Sarepta Therapeutics Inc is "1SRPT."

What Is the Sarepta Therapeutics Inc Market Cap?

As of today, Sarepta Therapeutics Inc market cap is 998.57M.

What Is Sarepta Therapeutics Inc's Earnings Per Share (TTM)?

The Sarepta Therapeutics Inc EPS (TTM) is -2.59.

From a Technical Analysis Perspective, Is 1SRPT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Sarepta Therapeutics Inc Stock Split?

Sarepta Therapeutics Inc has split 0 times.

How Many Employees Does Sarepta Therapeutics Inc Have?

Sarepta Therapeutics Inc has 1372 employees.

What is the current trading status of Sarepta Therapeutics Inc (1SRPT)?

As of 28 Jul 2025, Sarepta Therapeutics Inc (1SRPT) is trading at a price of 10.19, with a previous close of 10.19. The stock has fluctuated within a day range of 9.33 to 10.40, while its 52-week range spans from 9.33 to 37.16.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.